MWPCG
ZVRA icon

Measured Wealth Private Client Group’s Zevra Therapeutics ZVRA Stock Holding History

Measured Wealth Private Client Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$49K – 208
2024
Q2 		$49K Hold
10,000
– – 0.02% 185
2024
Q1 		$58K Hold
10,000
– – 0.02% 184
2023
Q4 		$65.5K Hold
10,000
– – 0.02% 175
2023
Q3 		$48.2K Buy
+10,000
New +$49.9K 0.02% 165

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Measured Wealth Private Client Group's ZVRA Position: Q3 2024 in Review

Measured Wealth Private Client Group sold out of Zevra Therapeutics (ZVRA) in Q3 2024, closing a stake of 10,000 shares — an estimated $49K sold.

Measured Wealth Private Client Group first reported a position in ZVRA in Q3 2023 and held it in 4 quarters. The position peaked at $65.5K in Q4 2023. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

  • Measured Wealth Private Client Group reported no remaining Zevra Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Measured Wealth Private Client Group sold 10,000 Zevra Therapeutics shares in Q3 2024, an estimated $49K.
  • Measured Wealth Private Client Group first reported a position in Zevra Therapeutics in Q3 2023 and held it in 4 quarters.
  • Measured Wealth Private Client Group's Zevra Therapeutics position peaked at $65.5K in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on Measured Wealth Private Client Group's 13F filing for Q3 2024, filed 28 Oct 2024.